The Particulars: Radioembolization with yttrium-90 (Y-90) radioactive beads plus chemotherapy may offer a survival benefit when compared with standard therapy for patients with liver-dominant metastases from colorectal cancer.
Data Breakdown: For a study, 39 patients with liver-dominant metastases from colorectal cancer underwent Y-90 radioembolization. Survival averaged approximately 11 to 12 months longer for participants than historical survival estimates for counterparts who received standard therapy with chemotherapy and biologics alone.
Take Home Pearl: Radioembolization with Y-90 radioactive beads plus chemotherapy appears to extend survival by nearly 1 year when compared with standard therapy alone in patients with liver-dominant metastases from colorectal cancer.
